These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 28381544)

  • 1. Modulation of Bax and mTOR for Cancer Therapeutics.
    Li R; Ding C; Zhang J; Xie M; Park D; Ding Y; Chen G; Zhang G; Gilbert-Ross M; Zhou W; Marcus AI; Sun SY; Chen ZG; Sica GL; Ramalingam SS; Magis AT; Fu H; Khuri FR; Curran WJ; Owonikoko TK; Shin DM; Zhou J; Deng X
    Cancer Res; 2017 Jun; 77(11):3001-3012. PubMed ID: 28381544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
    Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
    Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oridonin inhibits mTOR signaling and the growth of lung cancer tumors.
    Wang YY; Lv YF; Lu L; Cai L
    Anticancer Drugs; 2014 Nov; 25(10):1192-200. PubMed ID: 25075795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mono- or double-site phosphorylation distinctly regulates the proapoptotic function of Bax.
    Wang Q; Sun SY; Khuri F; Curran WJ; Deng X
    PLoS One; 2010 Oct; 5(10):e13393. PubMed ID: 20976235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5,3'-Dihydroxy-6,7,4'-trimethoxyflavanone exerts its anticancer and antiangiogenesis effects through regulation of the Akt/mTOR signaling pathway in human lung cancer cells.
    Kim KM; Heo DR; Lee J; Park JS; Baek MG; Yi JM; Kim H; Bang OS
    Chem Biol Interact; 2015 Jan; 225():32-9. PubMed ID: 25446852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule Bax agonists for cancer therapy.
    Xin M; Li R; Xie M; Park D; Owonikoko TK; Sica GL; Corsino PE; Zhou J; Ding C; White MA; Magis AT; Ramalingam SS; Curran WJ; Khuri FR; Deng X
    Nat Commun; 2014 Sep; 5():4935. PubMed ID: 25230299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
    Belmont PJ; Jiang P; McKee TD; Xie T; Isaacson J; Baryla NE; Roper J; Sinnamon MJ; Lee NV; Kan JL; Guicherit O; Wouters BG; O'Brien CA; Shields D; Olson P; VanArsdale T; Weinrich SL; Rejto P; Christensen JG; Fantin VR; Hung KE; Martin ES
    Sci Signal; 2014 Nov; 7(351):ra107. PubMed ID: 25389372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
    Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
    Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.
    Dai B; Yan S; Lara-Guerra H; Kawashima H; Sakai R; Jayachandran G; Majidi M; Mehran R; Wang J; Bekele BN; Baladandayuthapani V; Yoo SY; Wang Y; Ying J; Meng F; Ji L; Roth JA
    PLoS One; 2015; 10(6):e0123967. PubMed ID: 26053020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.
    Dogan Turacli I; Ozkan AC; Ekmekci A
    Tumour Biol; 2015 Dec; 36(12):9339-45. PubMed ID: 26108998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro.
    Xiao P; Sun LL; Wang J; Han RL; Ma Q; Zhong DS
    Acta Pharmacol Sin; 2015 Sep; 36(9):1107-12. PubMed ID: 26027660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001.
    Loehberg CR; Strissel PL; Dittrich R; Strick R; Dittmer J; Dittmer A; Fabry B; Kalender WA; Koch T; Wachter DL; Groh N; Polier A; Brandt I; Lotz L; Hoffmann I; Koppitz F; Oeser S; Mueller A; Fasching PA; Lux MP; Beckmann MW; Schrauder MG
    Biochem Pharmacol; 2012 Feb; 83(4):480-8. PubMed ID: 22142888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paris saponin I induces apoptosis via increasing the Bax/Bcl-2 ratio and caspase-3 expression in gefitinib-resistant non-small cell lung cancer in vitro and in vivo.
    Jiang H; Zhao PJ; Su D; Feng J; Ma SL
    Mol Med Rep; 2014 Jun; 9(6):2265-72. PubMed ID: 24718383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superoxide activates mTOR-eIF4E-Bax route to induce enhanced apoptosis in leukemic cells.
    Chaudhuri J; Chowdhury AA; Biswas N; Manna A; Chatterjee S; Mukherjee T; Chaudhuri U; Jaisankar P; Bandyopadhyay S
    Apoptosis; 2014 Jan; 19(1):135-48. PubMed ID: 24052408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.
    D'Abronzo LS; Bose S; Crapuchettes ME; Beggs RE; Vinall RL; Tepper CG; Siddiqui S; Mudryj M; Melgoza FU; Durbin-Johnson BP; deVere White RW; Ghosh PM
    Oncogene; 2017 Nov; 36(46):6359-6373. PubMed ID: 28745319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
    Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S
    Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. piR-55490 inhibits the growth of lung carcinoma by suppressing mTOR signaling.
    Peng L; Song L; Liu C; Lv X; Li X; Jie J; Zhao D; Li D
    Tumour Biol; 2016 Feb; 37(2):2749-56. PubMed ID: 26408181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway.
    Shi H; Pu J; Zhou XL; Ning YY; Bai C
    Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.
    Politz O; Siegel F; Bärfacker L; Bömer U; Hägebarth A; Scott WJ; Michels M; Ince S; Neuhaus R; Meyer K; Fernández-Montalván AE; Liu N; von Nussbaum F; Mumberg D; Ziegelbauer K
    Int J Cancer; 2017 Jan; 140(2):449-459. PubMed ID: 27699769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.